{
  "trial_id": "NCT00306813",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Age > 18 years at the time of signing the informed consent form.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Multiple myeloma with Durie-Salmon stage II or III and considered to have disease progression after at least 1 previous anti-myeloma regimen.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Subjects must have not have recieved more than 3 previous anti-myeloma regimens and must be relapsed or refractory following at least one regimen of anti-myeloma therapy.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Patients must have measurable levels of myeloma paraprotein in serum (>0.5 g/dl) or urine (>0.2 g excreted in a 24-hour collection sample).",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting each cycle. Men and WCBP must agree to use adequate contraceptive methods.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Must have a 2-d echocardiogram indicating LVEF \u2265 55% within 42 days prior to first dose of study drug.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Life extpectancy > 3 months.",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant or lactating females.",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Heart failure (EF < 55%).",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Any of the following laboratory abnormalities Absolute neutrophil count (ANC) <1500/mm3 (1x109/L).",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Prior history of any other malignancies except for adequately treated basal cell, insitu cervical or breast cancer or other for which the patient has been disease free for 5 years.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has multiple myeloma with relapse and is on hemodialysis. She has a history of hypercalcemia, but was treated with pamidronate and dialysis. The patient's life expectancy is unknown.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT00306813",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}